---
title: "ICH E6(R3) explained: good clinical practice | Quantlix"
description: "ICH E6(R3) is the international good clinical practice guideline for drug trials. Learn what changed, the EU and FDA dates, Annex 2 and the impact on trial software."
canonical: "https://quantlix.com/en/standards/ich-e6/"
last-updated: 2026-11-16
---

Source: https://quantlix.com/en/standards/ich-e6/
Language: en
Description: ICH E6(R3) is the international good clinical practice guideline for drug trials. Learn what changed, the EU and FDA dates, Annex 2 and the impact on trial software.

**ICH E6** [Quality and regulated operations](https://quantlix.com/en/standards/#quality)

# ICH E6(R3): the international guideline for good clinical practice

ICH E6 is the international guideline for good clinical practice (GCP), the ethical and quality standard for designing, running, recording and reporting clinical trials of medicines. E6(R3) is the current revision.

[Discuss your project](https://quantlix.com/en/contact/) [Read the key points](https://quantlix.com/en/standards/ich-e6/#standard-overview)

## At a glance

**Full name**

ICH Harmonised Guideline: Guideline for Good Clinical Practice E6(R3)

**Published by**

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)

**Type**

International guideline, implemented by regulators such as EMA and FDA

**Current version**

E6(R3) principles and Annex 1 adopted January 6, 2025 (EU effective July 23, 2025; FDA guidance September 2025); Annex 2 adopted June 3, 2026, EU effective January 15, 2027

**Applies to**

Sponsors, investigators, ethics committees, contract research organizations and service providers in interventional trials of investigational products

**Last reviewed**

November 16, 2026 (2026-11-16)

## In plain terms

### Key points

- E6(R3) replaces E6(R2) with 11 principles and annexes, written to fit different trial designs, settings and technologies.
- It asks for quality built into trial design and risk-proportionate processes that focus on what matters for participants and reliable results.
- A new data governance section covers the data lifecycle, metadata and audit trails, and the validation, security and use of computerized systems.
- In the EU, the principles and Annex 1 apply from July 23, 2025, and Annex 2 on decentralized, pragmatic and real-world data elements from January 15, 2027.

### What is ICH E6?

ICH E6 is **the international guideline for good clinical practice (GCP)** in trials of medicines. It is published by the International Council for Harmonisation (ICH), which brings together medicines regulators and the pharmaceutical industry, and it sets the ethical and scientific quality standard for how trials are designed, conducted, recorded and reported.

GCP protects the rights, safety and well-being of participants and makes trial results reliable enough for regulators to base decisions on. Because ICH regulators implement the same guideline, a trial run to E6 can support submissions in several regions.

### What E6(R3) covers

- **Eleven principles.** Ethics, informed consent, independent ethics review, sound science, qualified people, quality built into design, risk-proportionate processes, a clear and feasible protocol, reliable results, clear roles and investigational products made to GMP.
- **Ethics committees and investigators.** Responsibilities of institutional review boards and independent ethics committees, and of investigators for participant care, safety reporting and informed consent.
- **Sponsor responsibilities.** Trial design, agreements, oversight of service providers, quality and risk management, monitoring, safety reporting and investigational product handling.
- **Data governance.** The data lifecycle from capture through metadata, audit trails, review, correction, transfer, retention and destruction, plus the procedures, security, validation and user management of computerized systems.
- **Supporting appendices.** Content for the investigator’s brochure, the protocol and the essential records that document a trial.
- **Annex 2.** Additional considerations for decentralized elements, pragmatic designs and real-world data sources.

### Key dates

**ICH adopted E6(R3), with its principles and Annex 1, on January 6, 2025**, replacing E6(R2) from 2016. In the EU, it came into effect on July 23, 2025. FDA published it as final guidance in September 2025, and other ICH regulators are implementing it on their own timelines.

Annex 2 followed. ICH adopted it on June 3, 2026, EMA published it together with a consolidated E6(R3) in July 2026, and it comes into effect in the EU on January 15, 2027. When we checked in November 2026, FDA’s page for Annex 2 still showed its December 2024 draft, so US teams should watch for the final version.

### How it shows up in software projects

- **Fit-for-purpose validation.** Trial systems such as electronic data capture (EDC), electronic clinical outcome assessment (eCOA), randomization and the electronic trial master file (eTMF) are validated in proportion to their risk to participants and results.
- **Audit trails and metadata.** Systems keep metadata and audit trails that show who entered or changed data, when and why, and these are reviewed during the trial.
- **Access and blinding.** Role-based access protects the blind and limits who can see unblinded data.
- **Decentralized and real-world data.** Remote visits, digital health technologies and data from health records need clear data flows, source identification and privacy controls.
- **Service provider oversight.** Sponsors keep oversight of vendors and their systems through agreements, qualification and ongoing review.

### How we work with ICH E6

We build and integrate clinical trial software for [life sciences](https://quantlix.com/en/industries/life-sciences/) sponsors and research organizations: data capture apps, integrations between EDC, safety and data platforms and analytics that support risk-based monitoring. We design data flows to the E6(R3) data governance expectations and to [CDISC](https://quantlix.com/en/standards/cdisc/) structures, with electronic record controls aligned with [21 CFR Part 11](https://quantlix.com/en/standards/21-cfr-part-11/) and privacy designed around [GDPR](https://quantlix.com/en/standards/gdpr/) or [HIPAA](https://quantlix.com/en/standards/hipaa/).

GCP compliance belongs to sponsors and investigators, overseen by ethics committees and regulators. We supply systems, validation evidence and documentation that support their work.

## Where it applies

Industries where this standard often shapes the work.

- ### [Pharmaceuticals & Life Sciences](https://quantlix.com/en/industries/life-sciences/)

  Research data, pharmaceutical operations and biotechnology platforms

## Related standards

[All standards](https://quantlix.com/en/standards/)

- CDISC

  ### [Clinical trial data standards](https://quantlix.com/en/standards/cdisc/)

  CDISC is a global nonprofit whose clinical research data standards, such as SDTM, ADaM and Define-XML, are required by FDA and Japan's PMDA for study data in drug submissions.
- 21 CFR Part 11

  ### [FDA electronic records and signatures](https://quantlix.com/en/standards/21-cfr-part-11/)

  21 CFR Part 11 is the FDA regulation that sets the conditions under which electronic records and electronic signatures are trusted as equivalent to paper records and handwritten signatures.
- GDPR

  ### [EU personal data protection law](https://quantlix.com/en/standards/gdpr/)

  GDPR is the European Union regulation that sets how organizations collect, use, share and protect personal data about people in the EU, giving individuals clear rights and every controller and processor clear duties.
- HIPAA

  ### [US health information privacy and security](https://quantlix.com/en/standards/hipaa/)

  HIPAA is the US federal law whose Privacy, Security and Breach Notification Rules govern how health plans, providers and their business associates use, disclose and protect patient health information.

## Services that support this work

The services we usually bring to projects that involve this standard.

[View all services](https://quantlix.com/en/services/)

### [Enterprise applications](https://quantlix.com/en/services/enterprise-applications/)

Quantlix designs and builds enterprise applications for internal workflows, business rules and system integration, with clear access controls and maintainable architecture.

### [Data analytics](https://quantlix.com/en/services/data-analytics/)

Quantlix builds analytics pipelines and business intelligence tools that turn operational data into defined metrics, useful reports and decision support.

### [Mobile app development](https://quantlix.com/en/services/mobile-app-development/)

Quantlix builds mobile applications for iOS and Android, connecting device capabilities and business services through clear, accessible mobile experiences.

## Questions, answered

What teams usually ask us about this standard.

**Is ICH E6(R3) mandatory?**

ICH guidelines take effect through each regulator. EMA applied the E6(R3) principles and Annex 1 from July 23, 2025, and FDA published them as guidance in September 2025, alongside its binding clinical trial regulations. Inspectors use E6 as the reference for good clinical practice.

**What changed from E6(R2) to E6(R3)?**

E6(R3) was rewritten rather than amended. It is organized as principles with annexes, gives more weight to quality by design, risk proportionality and fit-for-purpose approaches, and sets clearer expectations for data governance and the computerized systems used in trials.

**What is ICH E6(R3) Annex 2?**

Annex 2 gives additional GCP considerations for trials that include decentralized elements, pragmatic elements or real-world data sources. ICH adopted it on June 3, 2026, and it comes into effect in the EU on January 15, 2027.

**What does E6(R3) mean for clinical trial software?**

Systems such as EDC, eCOA, randomization and eTMF must be fit for purpose, validated in proportion to risk, secure and able to show who did what and when through audit trails. Sponsors keep overall responsibility for systems and services that vendors provide.

**Does ICH E6 apply to medical device trials?**

E6 is written for clinical trials of investigational products, meaning medicines, vaccines and biological products. Device investigations follow their own requirements and standards, such as ISO 14155, although many device sponsors draw on E6 principles.

## Official sources

Read the official text before relying on any detail. What applies to you depends on your role, your location and the version in force.

- [ICH efficacy guidelines (E6 Good Clinical Practice)](https://www.ich.org/page/efficacy-guidelines)
- [EMA: ICH E6 good clinical practice](https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline)
- [FDA: E6(R3) Good Clinical Practice guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r3-good-clinical-practice-gcp)

These guides explain each standard in plain terms. They are not legal advice, and they do not state that any product or organization conforms to a standard.

## Planning software around this standard?

Tell us which systems are involved and what you need to show. We will help you build the requirements in from the start.

[Discuss your project](https://quantlix.com/en/contact/)
